+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer



The association of human papillomavirus type 16 E6 and E7 antibodies with stage of cervical cancer



Gynecologic Oncology 61(1): 73-78



Previous investigators have reported higher HPV type 16 antibody positivity among cervical cancer patients than among healthy women. The objective of this study was to determine the association of HPV 16 antibody levels with the stage of cervical cancer. Pretreatment tumor biopsies and sera were obtained from 137 newly diagnosed cervical cancer patients residing in Mexico. Using peptide ELISA and radioimmunoprecipitation assay (RIPA), HPV 16 E6- and E7-specific antibodies were measured. By ELISA, elevated antibody titers to HPV 16 E6 and E7 were detected in 16.8 and 32.8% of the women, respectively. While sera positivity did not differ by disease stage, the mean absorbance in the E7-positive sera was 0.42, 0.62, 0.91, and 0.81 for stages I to IV, respectively. Using RIPA, anti-E6 and E7 positivity was demonstrated in 46.7 and 38.7% of the females, respectively. Although no difference across disease stage was detected for E6, increasing proportions of positivity to E7 with stage of disease was detected. The rates for increasing disease stage were 0.14, 0.37, 0.40, and 0.67. Sera from the 6-month postradiation follow-up examinations of a small group of patients demonstrated a statistically significant decrease in antibody positivity from pretreatment positivity to HPV 16 E6 (n = 14; P = 0.01) and HPV 16 E7 (n = 20; P = 0.0001) using ELISA. These data suggest that HPV 16 E7 antibody positivity may be associated with stage of cervical cancer. Such immune parameters may be applicable to disease staging, monitoring of recurrence and, perhaps, diagnosis. Further investigation into the relationship of HPV 16 E6 and E7 antibodies with stage of cervical cancer and response to therapy is warranted.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009543843

Download citation: RISBibTeXText

PMID: 8626121

DOI: 10.1006/gyno.1996.0099


Related references

Independent association of antibodies against human papillomavirus type 16 E1/E4 and E7 proteins with cervical cancer. Virology 190(2): 724-732, 1992

Human papillomavirus type 18: Association with poor prognosis in early stage cervical cancer. Journal of the National Cancer Institute 88(19): 1361-1368, 1996

Association of the antibodies against human papillomavirus 16 E4 and E7 proteins with cervical cancer positive for human papillomavirus DNA. International Journal Of Cancer. 54(4): 624-628, 1993

The association of human papillomavirus antibodies with cervical cancer risk. Cancer Epidemiology, Biomarkers & Prevention 1(4): 281-286, 1992

Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease. Journal of General Virology 89(Pt 4): 910-914, 2008

The inspection of human papillomavirus type 16 E6,E7 antibodies in human sera with cervical cancer. Xi'an Yike Daxue Xuebao 15(4): 311-313, 1994

Association of serum antibodies against defined epitopes of human papillomavirus L1, E2, and E7 antigens and of HPV DNA with incident cervical cancer. Cancer Detection and Prevention 19(5): 381-393, 1995

Association between human papillomavirus type 18 variants and histopathology of cervical cancer. Journal of the National Cancer Institute 89(16): 1227-1231, 1997

Association of human papillomavirus type 58 variant with the risk of cervical cancer. Journal of the National Cancer Institute 94(16): 1249-1253, 2002

Human papillomavirus type 18 E6 and E7 antibodies in human sera: increased anti-E7 prevalence in cervical cancer patients. Journal of Clinical Microbiology 29(8): 1579-1588, 1991

Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. Journal of the National Cancer Institute 81(22): 1698-1704, 1989

The association of human papillomavirus type 16 E2 variations with cervical cancer in a Han Chinese population. Infection, Genetics and Evolution 64: 241-248, 2018

Differences in human papillomavirus type may influence clinical outcome in early stage cervical cancer. Anticancer Research 26(2a): 829-832, 2006

Prevalence of serum IgG antibodies for the E7 and L2 proteins of human papillomavirus type 16 in cervical cancer patients and controls. Tohoku Journal of Experimental Medicine 170(2): 113-121, 1993

Association of human papillomavirus type 16 long control region mutation and cervical cancer. Virology Journal 10: 30, 2014